Hjem › Sigdcelleanemi › Alabama
Kliniske studier for Sigdcelleanemi i Alabama
16 studier for Sigdcelleanemi søker deltakere på steder i Alabama.
Byer i Alabama
Offisiell studietekst (engelsk)
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- University Of Alabama, Birmingham
RekruttererFase 3
Alder 12 til 100 · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06439082A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- University of Alabama at Birmingham, Birmingham
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07187973A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Uni of Alabama at Birmingham, Birmingham
- Univer South Alabama Ped/Onc, Mobile
RekruttererFase 3
Alder 12 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT06612268A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- University of Alabama Birmingham, Birmingham
RekruttererFase 1/2Frivillige helsepersonell ønskes velkommen
Alder 12 til 55 · Alle kjønn · Oppdatert 9. sep. 2026 · NCT06546670SCD Stem Cell Mobilization and Apheresis Using Motixafortide
- University of Alabama at Birmingham, Birmingham
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06442761A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
- University of Alabama at Birmingham, Birmingham
RekruttererFase 1/2Frivillige helsepersonell ønskes velkommen
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT06481306A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- AMR Clinical, Mobile
RekruttererFase 2/3
Alder 12 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT05431088The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- University of Alabama at Birmingham- Site Number : 8400003, Birmingham
RekruttererFase 3
Alder 10 til 65 · Alle kjønn · Oppdatert 29. jul. 2026 · NCT06975865Early Life Exposures Among Children With Sickle Cell Disease
- University of Alabama at Birmingham, Birmingham
Rekrutterer
Alder 18 til 50 · Kvinner · Oppdatert 15. jul. 2026 · NCT05377372Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
- University Of Alabama, Birmingham
RekruttererFase 4
6 Months – 100 Years · Alle kjønn · Oppdatert 8. jun. 2026 · NCT04657822Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
- Children's of Alabama (MRD-HCT), Birmingham
- Children's of Alabama (NT-DMT), Birmingham
RekruttererObservasjonsstudie
Alder 3 til 20 · Alle kjønn · Oppdatert 4. jun. 2026 · NCT06941389Cognitive Remediation Intervention to Prepare for Transition of Care
- University of Alabama at Birmingham, Birmingham
RekruttererFase 2
Alder 10 til 18 · Alle kjønn · Oppdatert 27. feb. 2026 · NCT05336201A Long-term Follow-up Study in Patients Who Received BEAM-101
- University of Alabama at Birmingham, Birmingham
RekruttererObservasjonsstudie
Alder 14 til 37 · Alle kjønn · Oppdatert 28. jan. 2026 · NCT07373639Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
- University of South Alabama Medical Center, Mobile
Rekrutterer
Alder 16 til 30 · Alle kjønn · Oppdatert 7. jan. 2026 · NCT06374238HPC Offered for PRESERVE Expansion
- University of Alabama, Birmingham, Birmingham
RekruttererObservasjonsstudie
Alder 12 til 80 · Alle kjønn · Oppdatert 28. aug. 2025 · NCT07145411Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
- University of Alabama, Birmingham (UAB), Birmingham
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 22. jun. 2025 · NCT06385886Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.